INO 3106

Drug Profile

INO 3106

Alternative Names: INO-3106

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals; University of Pennsylvania
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Head and neck cancer; Human papillomavirus infections; Lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Human-papillomavirus-infections in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-cancer in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top